Names Medilens Nordic AB Its First Authorized European Distributor
for the NaturalVue® Brand Contact Lenses
ATLANTA–(BUSINESS WIRE)–Visioneering Technologies, Inc. (ASX: VTI), an innovative US-based
medical device company dedicated to developing advanced products that
improve vision, today announced that Medilens Nordic AB has been named
an Authorized Distributor for the innovative NaturalVue® (etafilcon A)
Brand 1 Day Contact Lenses. One of the leading ophthalmology-focused
medical device companies in the Nordic region and headquartered in
Helsingborg, Sweden, Medilens Nordic AB is Visioneering’s first European
distributor. This partnership marks Visioneering’s entry into the
Medilens Nordic AB operates in Sweden, Norway, Denmark, Finland and
Iceland, providing a large suite of products to Eye Care Professionals
(ECPs). Important to VTI, Medilens Nordic employs a highly trained sales
force that includes opticians, pharmacists, and other technically
trained specialists that call on over 1400 ECPs.
“Medilens Nordic strives to maintain leadership in our field by
providing our customers with the very best products, expertise, services
and value,” said Kent Maack, Managing Director. “We believe that
Visioneering’s revolutionary NaturalVue® 1 Day Contact Lenses are taking
us to the leading edge of vision technology. We’re thrilled to be the
first distributor to introduce these new contact lenses in not only the
Nordic region, but also the first in all of Europe.”
“Medilens Nordic is an ideal partner for Visioneering not only for their
stellar reputation, but also because they work closely with eye care
professionals in both public and private healthcare,” said Tony Sommer,
Senior Vice President of Sales and Marketing for VTI. “Maintaining close
relationships with eye care professionals is our sweet spot. It’s core
to our marketing philosophy, just as it is to Medilens Nordic’s. We’re
looking forward to a long and productive relationship with them.”
About Visioneering Technologies, Inc.
Visioneering Technologies, Inc. (VTI) is a US-based medical device
company primarily engaged in the design, manufacture, sale and
distribution of a revolutionary new contact lens: the NaturalVue®
Multifocal (MF) contact lens. The NaturalVue MF contact lens employs
VTI’s Neurofocus Optics® technology, which was developed, refined and
tested over many years. The characteristics of the NaturalVue MF contact
lens allow it to be used in two of the largest eye-care markets
globally: adults with presbyopia (age-related difficulty in seeing close
objects) and children with myopia (near-sightedness, or difficulty
seeing distant objects).
NaturalVue lenses were cleared by the FDA in late 2014 and received the
CE Mark, as well as TGA and MedSafe approval in early 2018. VTI recently
commenced its US market expansion for NaturalVue MF contact lenses in
2017, and has broadened its reach into international markets in 2018.
VTI also sells and plans additional contact lens products.
Foreign Ownership Restriction:
VTI’s CHESS Depositary Interests (CDIs) are issued in reliance on the
exemption from registration contained in Regulation S of the US
Securities Act of 1933 (Securities Act) for offers or sales which are
made outside the US. Accordingly, the CDIs have not been, and will not
be, registered under the Securities Act or the laws of any state or
other jurisdiction in the US. The holders of VTI’s CDIs are unable to
sell the CDIs into the US or to a US person unless the re-sale of the
CDIs is registered under the Securities Act or an exemption is
available. Hedging transactions with regard to the CDIs may only be
conducted in accordance with the Securities Act.
This announcement contains or may contain forward-looking statements
that are based on management’s beliefs, assumptions and expectations and
on information currently available to management.
All statements that address operating performance, events or
developments that we expect or anticipate will occur in the future are
forward-looking statements. These include, without limitation, U.S.
commercial market acceptance and U.S. sales of our product as well as,
our expectations with respect to our ability to develop and
commercialize new products.
Management believes that these forward-looking statements are reasonable
when made. You should not place undue reliance on forward-looking
statements because they speak only as of the date when made. VTI does
not assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. VTI may not actually achieve the plans,
projections or expectations disclosed in forward-looking statements.
Actual results, developments or events could differ materially from
those disclosed in the forward-looking statements.